Viewing data from:

QUILLICHEW ER

NDA

METHYLPHENIDATE HYDROCHLORIDE | N207960 | NEXTWAVE PHARMACEUTICALS INC

3 strengths10 unique patents0 unique exclusivities

Patent Timeline

10 unique patents by expiration date

Expiring < 1yr (1)Active (9)Today

2027

2028

2029

2030

2031

2032

2033

Today

Mar. 15, 2027

Feb. 15, 2031

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

Aug. 14, 2033

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
TRIS PHARMA, INC. v. TEVA PHARMACEUTICALS USA, INC. 2:2020cv05212 4 patentsmethylphenidate (MPH)	D.N.J.	2020-04-28	Terminated 2022-09-22	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

286 trials from ClinicalTrials.gov — 5 recruiting, 5 active, 208 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer NCT03772834	Phase 2/3	Active	M.D. Anderson Cancer Center	200	2019-03-25 → 2026-11-30
Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness NCT03814356	Phase 1	Active	Massachusetts General Hospital	10	2020-08-24 → 2026-06-30
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy NCT03525873	Phase 3	Active	M.D. Anderson Cancer Center	212	2018-08-02 → 2026-12-31
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer NCT01628029	Phase 2	Active	M.D. Anderson Cancer Center	68	2014-01-15 → 2028-12-31
Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy NCT01410942	Phase 2	Active	M.D. Anderson Cancer Center	175	2012-02-08 → 2026-09-30
Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children NCT03425669	N/A	Recruiting	Lund University	70	2019-05-01 → 2027-05-31
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk NCT03781765	Phase 4	Recruiting	Icahn School of Medicine at Mount Sinai	44	2019-06-04 → 2025-09-25
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD NCT03781752	Phase 4	Recruiting	Icahn School of Medicine at Mount Sinai	500	2018-03-04 → 2025-08
The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome NCT00768820	Phase 4	Recruiting	The Chaim Sheba Medical Center	400	2001-05 → 2027-08
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder NCT02951754	Phase 4	Recruiting	Hospital de Clinicas de Porto Alegre	600	2002-02 → 2032-12

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$11.91

per ea

Lowest NADAC/Unit

$11.88

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
24478007401QUILLICHEW ER 20 MG CHEW TAB	$11.91	EA	Brand	—	2026-06-17
24478007501QUILLICHEW ER 30 MG CHEW TAB	$11.89	EA	Brand	—	2026-06-17
24478007601QUILLICHEW ER 40 MG CHEW TAB	$11.88	EA	Brand	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 6 NDCs (3 FSS, 3 Big4)

Lowest Price

$928.85

Highest Price

$1008.35

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
24478-0075-01QUILLICHEW ER 30MG TAB	$1008.35	FSS	Tris Pharma, Inc.	08/31/2028
24478-0075-01QUILLICHEW ER 30MG TAB	$929.02	Big4	Tris Pharma, Inc.	08/31/2028
24478-0074-01QUILLICHEW ER 20MG TAB	$1008.35	FSS	Tris Pharma, Inc.	08/31/2028
24478-0074-01QUILLICHEW ER 20MG TAB	$928.85	Big4	Tris Pharma, Inc.	08/31/2028
24478-0076-01QUILLICHEW ER 40MG TAB	$1008.35	FSS	Tris Pharma, Inc.	08/31/2028
24478-0076-01QUILLICHEW ER 40MG TAB	$929.05	Big4	Tris Pharma, Inc.	08/31/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Quillichew ER (2024)

Total Spending

$285K

Total Claims

644

Beneficiaries

110

Avg Cost/Unit

$12.47

Spending Trend

$114K(2019)→$136K(2020)→$185K(2021)→$201K(2022)→$260K(2023)→$285K(2024)

YoY Change:-5.6%

5yr CAGR:+0.9%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain12 active DMFs6 inactive

9 active API suppliers hold Drug Master Files for this ingredient.

VERANOVA LPMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 101371993

SPECGX LLCMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 127691997

CHATTEM CHEMICALS INCMETHYLPHENIDATE HYDROCHLORIDE, USP

DMF 163312002

CAMBREX CHARLES CITY INCMETHYLPHENIDATE HYDROCHLORIDE (RITALIN HCL)

DMF 166102003

CURIA MISSOURI INCMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 190632005

VERANOVA LPMETHYLPHENIDATE HYDROCHLORIDE, USP

DMF 195472006

NORAMCO LLCMETHYLPHENIDATE HYDROCHLORIDE

DMF 222442008

SPECGX LLCMETHYLPHENIDATE HYDROCHLORIDE USP (NP)

DMF 257762013

JANSSEN RESEARCH AND DEVELOPMENT LLCMETHYLPHENIDATE HYDROCHLORIDE DRUG SUBSTANCE (PROCESS I)

DMF 305102016

JANSSEN RESEARCH AND DEVELOPMENT LLCMETHYLPHENIDATE HYDROCHLORIDE DRUG SUBSTANCE (PROCESS II)

DMF 305462021

ALKEM LABORATORIES LTDMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 306822016

SIEGFRIED USA LLCMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 342742019

UCB INCInactiveMETHYLPHENIDATE HYDROCHLORIDE, USP

DMF 116351995

SIEGFRIED USA LLCInactiveMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 129891998

BOEHRINGER INGELHEIM CHEMICALS INCInactiveMETHYLPHENIDATE HYDROCHLORIDE

DMF 154852001

IPCA LABORATORIES LTDInactiveMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 206212007

MACFARLAN SMITH LTDInactiveMETHYLPHENIDATE HYDROCHLORIDE

DMF 305792016

CODY LABORATORIES INCInactiveMETHYLPHENIDATE HYDROCHLORIDE USP

DMF 335092019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

7 letters from Drugs@FDA

Date	Submission	Document
Mar 12, 2026	SUPPL -21	View Letter (PDF)
Sep 30, 2025	SUPPL -18	View Letter (PDF)
Oct 16, 2023	SUPPL -16	View Letter (PDF)
Jun 29, 2021	SUPPL -12	View Letter (PDF)
Mar 3, 2017	SUPPL -5	View Letter (PDF)
Jan 17, 2017	SUPPL -4	View Letter (PDF)
Dec 8, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 20MG

RLD

10 patents0 exclusivities▴

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | Approved: Dec 4, 2015

Patents (10) · 5 use codes

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8202537	Mar 15, 2027	—	—	Yes	—	—
8287903	Feb 15, 2031	—	—	Yes	—	—
8999386	Aug 14, 2033	—	—	Yes	—	—
9295642	Aug 14, 2033	—	—	Yes		—
9545399	Aug 14, 2033	—	—	Yes		—
9844544	Aug 14, 2033	—	—	Yes		—
10857143	Aug 14, 2033	—	—	Yes		—
11103494	Aug 14, 2033	—	—	Yes	—	—
11103495	Aug 14, 2033	—	—	Yes		—
11633389	Aug 14, 2033	—	—	Yes	—	—

#002 — 30MG

RLD

10 patents0 exclusivities▾

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | Approved: Dec 4, 2015

#003 — 40MG

RLD

10 patents0 exclusivities▾

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | Approved: Dec 4, 2015